What is the likely diagnosis and recommended treatment for a young female with chronic bilateral foot arthritis, no other joint involvement, rheumatoid factor negative, whose symptoms improve with steroids?

Likely Diagnosis: Seronegative Rheumatoid Arthritis or Juvenile Idiopathic Arthritis (Polyarticular Subtype)

In a young female with chronic bilateral foot arthritis, negative rheumatoid factor, and steroid-responsive symptoms, the most likely diagnosis is seronegative rheumatoid arthritis (if adult) or RF-negative polyarticular juvenile idiopathic arthritis (if under 16 years), and treatment should begin with methotrexate as the first-line DMARD, with NSAIDs as adjunct therapy and short-term bridging corticosteroids (≤3 months at ≤0.2 mg/kg/day, maximum 10 mg prednisone equivalent) during DMARD initiation. 1

Diagnostic Considerations

Key Clinical Features Supporting This Diagnosis:

• Bilateral foot involvement is common in RA, with approximately 20% of RA patients presenting initially with foot and ankle symptoms 2
• RF-negative status occurs in 21.3% of RA patients and does not exclude the diagnosis 3
• Steroid responsiveness is characteristic of inflammatory arthritis, with 76-95% of patients responding to corticosteroids 1
• Isolated foot arthritis without other joint involvement is less typical but can occur, particularly in early disease 2

Critical Differential Diagnosis to Exclude:

Before confirming RA/JIA, you must actively rule out:

• Spondyloarthropathies (psoriatic arthritis, reactive arthritis, enteropathic arthritis) - look for psoriasis, inflammatory bowel disease symptoms, enthesitis, dactylitis, or HLA-B27 positivity 4
• Adult-onset Still's disease - requires quotidian fever >39°C, evanescent rash, and systemic features 1
• Infection-related arthritis - particularly if acute onset
• Crystal arthropathy - though typically not bilateral and symmetric

Diagnostic Workup Required:

• Anti-CCP antibodies (more specific than RF for RA) 5, 6
• Inflammatory markers: ESR and CRP 5
• Complete blood count (looking for anemia, leukocytosis) 1
• Imaging: X-rays of feet to assess for erosions 5
• Consider HLA-B27 if spondyloarthropathy suspected 4

Treatment Algorithm

Initial Therapy (Treatment-Naïve Patient):

Step 1: Start DMARD Therapy Immediately

• Methotrexate is the first-line DMARD over leflunomide or sulfasalazine 1
• Dosing for adults: Start 10-15 mg/m² BSA weekly, can increase to maximum 25 mg weekly 1
• Subcutaneous route is preferred over oral if dose ≥15 mg/m² BSA or if inadequate response to oral 1
• For JIA patients: Oral methotrexate 10-<15 mg/m² BSA weekly initially; switch to subcutaneous if insufficient response 1

Step 2: Add Adjunct Therapies

• NSAIDs conditionally recommended for symptom management during DMARD initiation 1
• Bridging corticosteroids (prednisone ≤0.2 mg/kg/day, maximum 10 mg/day) for ≤3 months during DMARD initiation 1
• Corticosteroids enhance DMARD effects and are disease-modifying when used short-term 7

Step 3: Evaluate Response at 6-8 Weeks

• If no or minimal response after 6-8 weeks, consider changing or adding therapy 1
• Adequate methotrexate trial = 3 months before declaring failure 1

Subsequent Therapy for Inadequate Response:

If Moderate/High Disease Activity Despite Methotrexate Monotherapy:

• Adding a biologic to methotrexate is preferred over switching to second DMARD 1
• TNF inhibitor is first-choice biologic (adalimumab, etanercept, infliximab, golimumab) 1
• Continue methotrexate when adding biologic for synergistic effect 1

If First TNF Inhibitor Fails:

• Switch to non-TNFi biologic (tocilizumab or abatacept) over second TNFi for primary failure 1
• Consider second TNFi if secondary failure (good initial response then loss of efficacy) 1

If Second Biologic Fails:

• Use TNFi, abatacept, or tocilizumab (depending on prior biologics) over rituximab 1

Important Clinical Pitfalls and Caveats

Common Mistakes to Avoid:

1. Do NOT use NSAIDs as monotherapy for chronic persistent synovitis - they are inadequate for disease control and only 7-15% of patients respond to NSAID monotherapy 1

2. Do NOT use prolonged corticosteroids as monotherapy - limit to ≤3 months at lowest effective dose 1

   • Long-term corticosteroids cause significant toxicity (bone loss, growth suppression in children, metabolic effects) 1
   • 88% of patients eventually require prednisone, but 46% develop maintenance dependence if not properly managed 1

3. Do NOT delay DMARD initiation - early aggressive treatment with DMARDs is associated with better long-term outcomes 5

4. Do NOT assume RF-negative means "not RA" - seronegative RA is a valid diagnosis when clinical features are consistent 4, 6

   • ACPA-negative patients often have higher disease activity at diagnosis with more swollen joints 6
   • Consider anti-PAD4 and anti-CarP antibodies as emerging biomarkers 6

5. Continuously re-evaluate ACPA/RF-negative patients - if first-line treatments fail, reconsider alternative diagnoses including spondyloarthropathies 6

Special Considerations for Young Females:

• If patient is under 16 years old, this is juvenile idiopathic arthritis (polyarticular subtype) and treatment follows JIA guidelines 1
• If reproductive age, discuss teratogenicity of methotrexate and need for contraception 5
• Screen for comorbidities (hepatitis B/C, tuberculosis) before starting biologics 5

Monitoring Requirements:

• Assess disease activity regularly using validated measures (CDAI, HAQ-DI for adults; cJADAS-10 for JIA) 1, 3
• Monitor for extra-articular manifestations (lungs, eyes, skin) 5
• High RF titers (when present) associate with worse outcomes and higher need for biologics 3

When to Consider Intra-articular Corticosteroids:

• For active monoarthritis or oligoarthritis in context of polyarticular disease 1
• Synovitis preventing ambulation or interfering with important daily activities 1
• Ideally use triamcinolone hexacetonide; if unavailable, use alternative depot corticosteroid 1

Duration of Therapy:

• Once inactive disease achieved on methotrexate, continue for at least 12 months before considering discontinuation 1
• Flare rates within 12 months of methotrexate withdrawal range 30-50% 1
• Taper corticosteroids first before tapering systemic DMARDs 1